In the current study, we employed adjunctive ZOL/IL-2 administrations in combination of TB drugs treatment of MDR-TB-infected NHP, and determined whether such adjunctive ZOL/IL-2 regimen could activate/differentiate protective Vγ2Vδ2 T effector cells and provide immunotherapeutic against MDR-TB in NHP. The gene discussed is IL2; the disease is multidrug-resistant tuberculosis.